Received Oct 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | — | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | — | — |
received 1st and 2nd dose at 8 and 9 years of age; Bexsero late third dose; This non-serious case was reported by a physician via call center representative and described the occurrence of drug dose administration interval too long in a 16-year-old patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included Men B NVS (Bexsero) for prophylaxis and Men B NVS (Bexsero) for prophylaxis. On 02-OCT-2025, the patient received the 3rd dose of Bexsero. On an unknown date, the patient received the 2nd dose of Bexsero and the 1st dose of Bexsero. On 02-OCT-2025, an unknown time after receiving Bexsero and not applicable after receiving Bexsero and Bexsero, the patient experienced drug dose administration interval too long (Verbatim: Bexsero late third dose). On an unknown date, the patient experienced inappropriate age at vaccine administration (Verbatim: received 1st and 2nd dose at 8 and 9 years of age). The outcome of the drug dose administration interval too long and inappropriate age at vaccine administration were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 04-OCT-2025 The physician reported that the Patient received 1 dose of Bexsero at age 8, 1 dose at age 9 and, 1 dose at age 16. The reporter was ask should patient receive another dose of Bexsero.